

Iris Dekker

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6696415/publications.pdf>

Version: 2024-02-01

16
papers

524
citations

687363

13
h-index

940533

16
g-index

16
all docs

16
docs citations

16
times ranked

971
citing authors

#	ARTICLE	IF	CITATIONS
1	Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2022, 28, 102-110.	3.0	13
2	A more unstable resting-state functional network in cognitively declining multiple sclerosis. <i>Brain Communications</i> , 2022, 4, .	3.3	8
3	Increased functional sensorimotor network efficiency relates to disability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1364-1373.	3.0	15
4	The sequence of structural, functional and cognitive changes in multiple sclerosis. <i>NeuroImage: Clinical</i> , 2021, 29, 102550.	2.7	21
5	Longitudinal Network Changes and Conversion to Cognitive Impairment in Multiple Sclerosis. <i>Neurology</i> , 2021, 97, e794-e802.	1.1	19
6	Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis. <i>Neurology</i> , 2021, 97, e1898-e1905.	1.1	32
7	Infratentorial and spinal cord lesions: Cumulative predictors of long-term disability?. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1381-1391.	3.0	22
8	The natalizumab wearing-off effect. <i>Neurology</i> , 2019, 93, e1579-e1586.	1.1	16
9	Cortical atrophy accelerates as cognitive decline worsens in multiple sclerosis. <i>Neurology</i> , 2019, 93, e1348-e1359.	1.1	53
10	Long-term disease activity and disability progression in relapsing-remitting multiple sclerosis patients on natalizumab. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 33, 82-87.	2.0	16
11	Predicting clinical progression in multiple sclerosis after 6 and 12 years. <i>European Journal of Neurology</i> , 2019, 26, 893-902.	3.3	40
12	Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study. <i>Lancet Neurology</i> , The, 2018, 17, 133-142.	10.2	98
13	Disease activity following pregnancy-related discontinuation of natalizumab in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e424.	6.0	15
14	Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1453-1460.	3.0	18
15	Predicting cognitive decline in multiple sclerosis: a 5-year follow-up study. <i>Brain</i> , 2018, 141, 2605-2618.	7.6	113
16	Brain and Spinal Cord MR Imaging Features in Multiple Sclerosis and Variants. <i>Neuroimaging Clinics of North America</i> , 2017, 27, 205-227.	1.0	25